Group 1 - The core viewpoint of the news is that Int Group's stock has shown a positive trend with a 2.04% increase on January 5, reaching a price of 13.01 yuan per share, with a total market capitalization of 6.872 billion yuan [1] - As of January 5, the stock has experienced a 5.00% increase over the last five trading days, a 2.60% increase over the last twenty days, and a 15.23% increase over the last sixty days [1] - The company primarily engages in the wholesale and retail of pharmaceuticals and medical devices, with 93.76% of its revenue coming from pharmaceutical sales, 5.67% from medical device sales, and 0.56% from other sources [1] Group 2 - As of December 19, the number of shareholders for Int Group has increased by 10.24% to 25,700, while the average number of circulating shares per person has decreased by 9.30% to 12,588 shares [2] - For the period from January to September 2025, Int Group reported a revenue of 24.963 billion yuan, reflecting a year-on-year growth of 0.75%, while the net profit attributable to shareholders decreased by 9.15% to 323 million yuan [2] - The company has distributed a total of 532 million yuan in dividends since its A-share listing, with 423 million yuan distributed over the past three years [3]

Group 1 - The core viewpoint of the news is that Aomei Medical has shown a mixed performance in its stock price and financial results, with a slight increase in stock price recently but a decline over the past few trading days [1][2]. - As of January 5, Aomei Medical's stock price increased by 2.01% to 11.14 CNY per share, with a market capitalization of 7.055 billion CNY [1]. - The company reported a revenue of 2.597 billion CNY for the first nine months of 2025, representing a year-on-year growth of 5.98%, and a net profit of 349 million CNY, which is a 31.54% increase compared to the previous year [2]. Group 2 - Aomei Medical's main business involves the research, production, and sales of disposable medical consumables, with the revenue composition being 79.19% from surgical and wound care, 6.62% from other categories, 5.05% from infection protection, 4.68% from advanced dressings, and 4.46% from hygiene care [1]. - The company has distributed a total of 1.099 billion CNY in dividends since its A-share listing, with 91.913 million CNY distributed over the past three years [3]. - As of September 30, 2025, the number of shareholders increased to 37,800, with an average of 11,965 circulating shares per person, a decrease of 0.71% [2][3].

Core Viewpoint - Chao Hong Ji's stock price has shown significant growth this year, but recent trading data indicates a decline in the short term, raising questions about future performance and investor sentiment [1][2]. Group 1: Stock Performance - On December 31, Chao Hong Ji's stock increased by 2.02%, reaching 12.62 CNY per share, with a trading volume of 68.46 million CNY and a turnover rate of 0.63%, resulting in a total market capitalization of 11.21 billion CNY [1]. - Year-to-date, Chao Hong Ji's stock price has risen by 131.14%, but it has experienced a decline of 2.32% over the last five trading days, 4.25% over the last 20 days, and 11.06% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Chao Hong Ji reported a revenue of 6.24 billion CNY, reflecting a year-on-year growth of 28.35%, while the net profit attributable to shareholders was 317 million CNY, showing a slight increase of 0.33% [2]. - The company's main revenue sources include fashion jewelry products (48.53%), traditional gold products (44.63%), brand authorization and franchise services (3.00%), leather goods (2.99%), and other income (0.86%) [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Chao Hong Ji was 35,300, a decrease of 12.70% from the previous period, with an average of 24,565 circulating shares per shareholder, an increase of 14.54% [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the third-largest shareholder with 64.54 million shares, a decrease of 877,600 shares from the previous period, and new entrants such as Hai Fu Tong Consumer Preferred Mixed A and Gold Stock ETF [3].

Group 1 - The core viewpoint of the news is that Shuiyang Co., Ltd. has shown significant stock performance and financial growth in 2023, with a notable increase in share price and revenue [1][2][3] Group 2 - As of December 31, Shuiyang's stock price increased by 2.02% to 22.20 CNY per share, with a total market capitalization of 8.658 billion CNY [1] - Year-to-date, Shuiyang's stock price has risen by 67.93%, with a 10.67% increase over the past 20 days [2] - The company reported a revenue of 3.409 billion CNY for the period from January to September 2025, reflecting a year-on-year growth of 11.96%, and a net profit of 136 million CNY, up 44.01% [2] - The main business revenue composition includes 81.84% from creams, 17.32% from masks, and 0.84% from other products [2] - Shuiyang has distributed a total of 142 million CNY in dividends since its A-share listing, with 77.8142 million CNY in the last three years [3] - As of September 30, 2025, the number of shareholders increased by 10.64% to 30,000, while the average circulating shares per person decreased by 9.61% to 11,966 shares [2][3]

Group 1 - The core viewpoint of the news is that Int Group's stock has experienced fluctuations, with a recent decline of 3.65% and a year-to-date increase of 20.68% [1] - As of December 19, 2025, Int Group reported a revenue of 24.963 billion yuan, reflecting a year-on-year growth of 0.75%, while the net profit attributable to shareholders decreased by 9.15% to 323 million yuan [2] - The company has distributed a total of 532 million yuan in dividends since its A-share listing, with 423 million yuan distributed in the last three years [3] Group 2 - Int Group's main business involves wholesale and retail of pharmaceuticals and medical devices, with pharmaceutical sales accounting for 93.76% of total revenue [1] - The company has seen an increase in the number of shareholders, reaching 25,700, which is a 10.24% increase from the previous period [2] - As of September 30, 2025, Hong Kong Central Clearing Limited is the sixth-largest circulating shareholder, holding 1.8963 million shares, an increase of 190,400 shares from the previous period [3]

Core Viewpoint - The stock of Chongqing Pharmaceutical Holdings has shown a significant increase in price this year, with a year-to-date rise of 21.68%, despite a recent decline in the last five trading days [1] Group 1: Stock Performance - As of December 26, the stock price reached 6.51 yuan per share, with a market capitalization of 11.25 billion yuan [1] - The stock has experienced a 4.82% decline over the last five trading days, but a 23.53% increase over the last 20 days and a 28.66% increase over the last 60 days [1] - The company has appeared on the trading leaderboard twice this year, with the most recent net purchase of 158 million yuan on December 15 [1] Group 2: Financial Performance - For the period from January to September 2025, the company reported a revenue of 62.21 billion yuan, reflecting a year-on-year growth of 4.22%, and a net profit attributable to shareholders of 384 million yuan, which is a 31.41% increase [2] - The company has distributed a total of 864 million yuan in dividends since its A-share listing, with 294 million yuan distributed in the last three years [3] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 4.05% to 42,000, while the average circulating shares per person increased by 4.22% to 41,112 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 10.09 million shares, an increase of 851,000 shares compared to the previous period [3]

Core Viewpoint - The stock of Chongqing Pharmaceutical Holdings Co., Ltd. has experienced fluctuations, with a recent decline of 2.01% and a year-to-date increase of 18.69% [1] Group 1: Stock Performance - As of December 25, the stock price is reported at 6.35 yuan per share, with a total market capitalization of 10.974 billion yuan [1] - The stock has seen a 7.43% decline over the last five trading days, but a 20.72% increase over the last 20 days and a 24.27% increase over the last 60 days [1] - The company has appeared on the "龙虎榜" (a stock trading leaderboard) twice this year, with the latest instance on December 15, where it recorded a net purchase of 1.58 billion yuan [1] Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 62.211 billion yuan, reflecting a year-on-year growth of 4.22% [2] - The net profit attributable to shareholders for the same period was 384 million yuan, showing a significant year-on-year increase of 31.41% [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders has decreased by 4.05% to 42,000, while the average circulating shares per person increased by 4.22% to 41,112 shares [2] - The company has distributed a total of 864 million yuan in dividends since its A-share listing, with 294 million yuan distributed over the last three years [3] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 10.091 million shares, an increase of 851,000 shares compared to the previous period [3]

Core Viewpoint - Water Goat Co., Ltd. has experienced a stock price increase of 62.25% this year, but recently faced a decline of 2.01% in the last five trading days, indicating potential volatility in its stock performance [2]. Group 1: Stock Performance - As of December 23, Water Goat's stock price is reported at 21.45 yuan per share, with a market capitalization of 8.366 billion yuan [1]. - The stock has seen a trading volume of 210 million yuan and a turnover rate of 2.70% [1]. - Year-to-date, the stock has been on the leaderboard once, with a net buy of 24.4889 million yuan on May 28 [2]. Group 2: Financial Performance - For the period from January to September 2025, Water Goat achieved a revenue of 3.409 billion yuan, reflecting a year-on-year growth of 11.96% [2]. - The net profit attributable to shareholders for the same period was 136 million yuan, marking a significant increase of 44.01% year-on-year [2]. Group 3: Shareholder Information - As of November 10, the number of shareholders for Water Goat reached 30,000, an increase of 10.64% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 9.61% to 11,966 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited and new entrants such as Huaxia Domestic Demand Driven Mixed A [3].

Core Viewpoint - Tonghua Jinma's stock price has shown significant growth this year, with an increase of 82.23% year-to-date, indicating strong market performance and investor interest [1][2]. Financial Performance - For the period from January to September 2025, Tonghua Jinma reported operating revenue of 892 million yuan, a year-on-year decrease of 7.88%, while net profit attributable to shareholders was 24.96 million yuan, reflecting a year-on-year increase of 4.35% [2]. - The company has cumulatively distributed 210 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Stock Market Activity - As of December 22, the stock price was 28.61 yuan per share, with a market capitalization of 27.651 billion yuan. The stock experienced a trading volume of 334 million yuan and a turnover rate of 1.23% [1]. - The stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) twice this year, with the most recent appearance on September 11, where it recorded a net buy of 142 million yuan [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders was 38,200, a decrease of 3.20% from the previous period, with an average of 25,266 shares held per shareholder, an increase of 3.31% [2]. - The top ten circulating shareholders include notable entities such as Innovation Drug and Southern CSI 1000 ETF, with varying changes in their holdings compared to the previous period [3].

Group 1 - The core viewpoint of the news is that潮宏基 has shown significant stock performance with a year-to-date increase of 134.43% and a recent trading volume indicating active market interest [1] - As of December 22,潮宏基's stock price reached 12.80 yuan per share, with a market capitalization of 11.373 billion yuan and a trading volume of 47.6085 million yuan [1] - The company has experienced a net inflow of main funds amounting to 3.3899 million yuan, with large orders accounting for 16.67% of total buying [1] Group 2 -潮宏基's main business includes the design, research and development, production, and sales of high-end fashion jewelry, with revenue contributions of 48.53% from fashion jewelry and 44.63% from traditional gold products [2] - As of September 30, 2025,潮宏基 reported a revenue of 6.237 billion yuan, reflecting a year-on-year growth of 28.35%, and a net profit of 317 million yuan, with a slight increase of 0.33% [2] - The company has distributed a total of 1.897 billion yuan in dividends since its A-share listing, with 800 million yuan distributed in the last three years [3]